iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Concord Biotech files a DRHP for an IPO with backing from Rare Enterprises and Quadria Capital

16 Aug 2022 , 04:06 PM

In order to raise money through an Initial Public Offering (IPO), Concord Biotech Limited, one of the top global developers and producers of specific fermentation-based APIs across immunosuppressants and oncology in terms of market share in 2021, has filed its Draft Red Herring Prospectus (DRHP) with the markets regulator, Securities and Exchange Board of India (SEBI).

The offering, which has a face value of Re1 per equity share, is a full offer for sale (OFS) by Helix Investment Holdings Pte. Limited, totaling 20,925,652 equity shares. The offer also permits qualified employees to reserve a subscription.

The offer is being made through the book building process, in which not less than 15% of the offer must be made available to non-institutional bidders, not less than 35% of the offer must be made available to retail individual bidders, and not more than 50% of the offer must be allocated to qualified institutional buyers.

According to the F&S report's DRHP, Concord Biotech will hold a market share of over 20% by volume in 2021 for the identified fermentation-based API products dactinomycin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine, among others. It provides goods to more than 70 nations, including regulated markets including the US, Europe, Japan, and India.

The DRHP adds that fermentation is a difficult process since it calls for managing several process parameters, working with microbial strains and cultures, and carrying out various purification procedures.
It has a portfolio of 56 brands and 65 products as of March 31, 2022, comprising 22 APIs and 43 formulations. They also supplied 80 out-licensed formulations under their own trademarks in India. It has submitted over 120 DMFs in a number of nations.
One of the few biopharma companies in the world that have effectively and sustainably created and expanded its fermentation-based API production capabilities is the Ahmedabad-based business. There are three production locations with a combined installed fermentation capacity of 1,250 m3 in the Gujarati state of Valthera, Dholka, and Limbasi.

Related Tags

  • Concord Biotech
  • DRHP
  • IPO
sidebar mobile


12 Apr 2024   |   01:37 PM
12 Apr 2024   |   10:20 AM
12 Apr 2024   |   10:16 AM
Read More

Most Read News

12 Apr 2024   |   08:25 PM
12 Apr 2024   |   08:14 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:08 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.


Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp